Caris Life Sciences (CAI) Stock Looks Like A Bargain On Cash Flow

Caris Life Sciences has delivered a 1 year gain that raises a straightforward question for anyone looking at the chart today. Is the current US$33.22 share price adequately backed by the cash flows that the business is expected to generate over time, or has sentiment moved ahead of the underlying economics?

• The stock is up 35.0% over the past year. This puts real weight on whether that climb is supported by the cash flows implied in the current valuation.
• Management recently reported higher revenue and lifted expectations for this year, which can affect how investors think about the timing and durability of future cash inflows that feed into an intrinsic value estimate.
• If you'd rather focus on earnings, this one's for you. See why Caris Life Sciences's 89.3x P/E tells a different valuation story.

For investors, the debate is whether the Discounted Cash Flow (DCF) view of Caris Life Sciences supports paying today's market price given the business's current and projected cash generation.

If you are weighing whether Caris Life Sciences justifies its current price on its cash flows, it can help to compare that question across 35 high quality undervalued stocks.

Does Caris Life Sciences Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) approach here is built around what Caris Life Sciences can generate in future free cash. On the latest figures, the business produced roughly $132.7 million of free cash flow over the past twelve months, and the 2 Stage Free Cash Flow to Equity model assumes that this cash generation grows over time rather than contracts.

Those projections rely on analyst forecasts through 2030, then on more moderate estimates after that. This points to a company expected to expand first and then settle into a steadier pattern. Because Caris Life Sciences recently raised its 2026 revenue guidance on the back of molecular profiling demand and new products, the stronger top line outlook helps explain why the DCF output sits modestly above the current US$33.22 share price. Find out what Caris Life Sciences could be worth using our Discounted Cash Flow (DCF) estimate.

The Caris Life Sciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Caris Life Sciences pick up where the valuation puzzle leaves off and spell out which paths for revenue, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price. Each storyline breaks that single DCF output into the future it relies on, so you can track whether Caris Life Sciences' actual progress still lines up with the scenario investors are pricing in on the Community page.

Community views on Caris Life Sciences split between those who see much more upside in the story and others who think the current price already reflects most of the good news.

Bull case: 55% undervalued

"Caris possesses the world's largest and most comprehensive clinico-genomic database. In 2025 alone, the company completed approximately 199,300 clinical therapy selection cases…"

Discover why this Narrative puts Caris Life Sciences at 55% undervalued.

Bear case: roughly fairly valued

"Heavier spending on whole genome early detection, sales and marketing or external opportunities could cap profitability and reduce free cash flow even if top line revenue continues to grow…"

Explore why this Narrative puts Caris Life Sciences at roughly fairly valued.

One more thing about Caris Life Sciences that deserves a closer look

Before drawing any conclusions on Caris Life Sciences, it helps to see what the broader checks have flagged about its risks and pressure points, since those can change how comfortable you feel with the story. Take a closer look at 2 warning signs before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com